Group items tagged

The proposed program's purpose is to increase the availability of supportive services for young breast cancer survivors (YBCS), young women with metastatic breast cancer (mBC), and their caregivers and families by supporting organizations and entities that serve this population. The awardees will address strategies relevant to the target audience. These include: the establishment of a network of survivors and caregivers to facilitate policy, system, and environmental change interventions that increases access to lifestyle programs, clinical preventive services, and cancer care among survivors; development and implementation of innovative technological educational opportunities for health care providers on topics relevant to the delivery of appropriate treatment and care of YBCS and mBC; and utilization of patient navigation and community health worker program strategies to reach underserved populations to enhance their access to and utilization of YBCS services and programs. To this end, activities funded by this NOFO, are intended to support organizations in closing the disparity gap needed to support young breast cancer survivors. Specifically, organizations will implement strategies that aim to reduce disparities observed in survival and quality of life due to race, ethnicity, or other social determinants of health. This NOFO will also support organizations in providing support services/programs to YBCS and mBC; and provide resources for health care providers in caring for all YBCS and mBC regardless of race, ethnicity, age, or sexual orientation during the period of performance of 09/30/2019-09/22/2024.

This UE5 funding opportunity announcement (FOA) is for a part of the NCIs Informatics Technology for Cancer Research (ITCR) program (https://itcr.cancer.gov/), and establishes an ITCR Education Center to provide education resources that will enhance the use and usability of the informatics tools and resources developed and supported by the ITCR program through education of both the cancer research community as well as informatics tool developers. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development The proposed Center will provide focused education courses in each of the following two areas (1) thematic topics in cancer informatics and (2) informatics tool usability and user support . The courses supporting education in thematic topics in cancer informatics should cover the variety of domains represented by the ITCR program and incorporate ITCR tools as exemplars for applying informatics methods, including, as appropriate, hands-on training on the associated tools and analysis workflows for participants. The courses in informatics tool usability and user support should focus on activities that target the needs of currently funded ITCR investigators, and provide guidance in enhancing the usability and user support of their tools.

Centers for Disease Control and Prevention (CDC) supports a variety of activities in health departments and organizations aimed at preventing and controlling cancer, the second leading cause of death in US men and women. Since the passage of the Cancer Registries Amendment Act in 1992, the National Program of Cancer Registries (NPCR) has collected data on cancer occurrence, extent, treatment and outcomes in over 45 states and jurisdictions, representing 96% of the US population. CDC's Division of Cancer Prevention and Control (DCPC) has supported successful partnerships with national organizations to define standardized practices in U.S. cancer surveillance and assure and complete, timely, and high-quality data for the official federal U.S. Cancer Statistics. The purpose of this funding opportunity is to build strong partnerships among national organizations involved directly in cancer surveillance in order to enhance the data quality and operational efficiency of CDC’s National Program of Cancer Registries (NPCR). This program has three essential components: 1) Education, Translation and Quality Control of cancer surveillance standards and best practices; 2) Cancer Staging Collaboration and Support; and 3) Standardization and Support for Laboratory and Biomarker Electronic Reporting. The overarching goal of this project is to collaboratively define and promote uniform standards in cancer staging, collection and reporting. Funded entities will identify specific enhancement needs of cancer registries and support cancer surveillance professionals, including reporters (e.g. facilities, labs), tumor registrars, and registries to submit high quality, standardized data via central cancer registries to NPCR. Relevant performance measures will be used to assess the recipients’ activities that enhance the standards, quality, and operations of NPCR cancer surveillance system.

This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support two types of cancer centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas. The purpose of both types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious programs in laboratory, clinical, and population research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of shared resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.

This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators. All awards are approved by the Board of Directors of the Damon Runyon Cancer Research Foundation acting upon the recommendation of the Innovation Award Committee.

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators. All awards are approved by the Board of Directors of the Damon Runyon Cancer Research Foundation acting upon the recommendation of the Innovation Award Committee.

The main goal of this limited competition Funding Opportunity Announcement (FOA) is to continue the state-of the-art biobanking infrastructure and operations for early-stage and experimental clinical trials sponsored by the National Cancer Institute (NCI). The biobanking needs of the following NCI clinical trial programs will be supported: Experimental Therapeutics Clinical Trials Network (ETCTN), and Other NCI-supported early and experimental trials. Currently, this biobanking infrastructure supporting NCI early experimental clinical trials is part of a biobank serving primarily another NCI program, National Clinical Trials Network (NCTN). Through a separate U24 award under this FOA, the NCI aims to separate the existing ETCTN-serving biobanking infrastructure and operation from the current NCTN Biobank. This separated entity will be termed: Early-Phase and Experimental Clinical Trials Biospecimen Bank (also referred to as EET Biobank). Although the EET Biobank and the "parent" NCTN Biobank may be hosted in the same institution, they are expected to become independent operations with separate leaderships. EET Biobank will be responsible for collecting, processing, storing a variety of human specimens from patients with cancer who are participating in NCI-funded ETCTN and other NCI-supported early and experimental clinical trials. The responsibilities of EET Bank will also include maintenance of up-to-date specimen inventory and specimen distribution to qualified NCI-approved trial investigators and research laboratories.

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this FOA is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" r "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. Research applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

The PRCRP Idea Award with Special Focus mechanism is intended to support innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research that are directly relevant to service members, their families, and other military beneficiaries. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The Idea Award with Special Focus is not intended to support a logical progression of an already established research project. The proposed research project should be novel and innovative. Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. Research that is an incremental advance upon published data is not considered innovative and will not be considered for funding under this award mechanism. Inclusion of preliminary data is discouraged. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for future research projects to understand the mechanisms of initiation, or progression of cancer. This award is not intended to support ongoing research in the applicant's laboratory; therefore, inclusion of preliminary data other than serendipitous findings or in very small numbers is not consistent with the exploratory nature of this award.

The Lung Cancer Research Foundation supports research on innovative strategies for better treatments, screening, and prevention of all cancers of the lung. The foundation's goal is to fund promising scientific and clinical research initiatives that lead to more positive outcomes and improved quality of life for all lung cancer patients.   To that end, LCRF has issued a Request for Proposals designed to provide critical seed support for cutting-edge scientific research on all lung cancers. Through its Research Grant program, the foundation will support projects with a focus on basic science, translational research, clinical research, supportive care, and quality of care/outcomes.   Grants of up to $75,000 will be awarded.   The program is open to all U.S. and international investigators, including graduate students, postdoctoral researchers, physicians, medical students, and nurse researchers.

The Lung Cancer Research Foundation supports research on innovative strategies for better treatments, screening, and prevention of all cancers of the lung. The foundation's goal is to fund promising scientific and clinical research initiatives that lead to more positive outcomes and improved quality of life for all lung cancer patients. To that end, LCRF has issued a Request for Proposals designed to provide critical seed support for cutting-edge scientific research on all lung cancers. Through its Research Grant program, the foundation will support projects with a focus on basic science, translational research, clinical research, supportive care, and quality of care/outcomes.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research projects addressing challenging cancer problems using systems biology approaches. In support of this goal, the National Cancer Institute (NCI) has initiated the Cancer Systems Biology Consortium (CSBC) through multiple FOAs. The CSBC network will consist of specialized U01 Research Projects (supported under this FOA), U54 CSBC Research Centers (supported under RFA-CA-15-014), and a U24 Coordinating Center (supported under RFA-CA-15-015).CSBC Research Projects should address a well-defined, discrete, and circumscribed research question in cancer incorporating quantitative experimentation, analysis, modeling and validation, which are the hallmarks of systems biology. As part of the CSBC, investigators from the Research Projects will have the opportunity to share resources and expertise across the Consortium and participate in Consortium activities and annual meetings.

The goal of this acquisition is to recruit health plan members from selected integrated health care systems (IHCS) into a complex, intensive, prospective cohort study, collect serial biospecimens and longitudinal data, and follow participants for disease outcomes, with a primary focus on cancer. The IHCS sites shall work with the National Cancer Institute (NCI) and others such as NCI third party contractors (support service and study information technology [IT] platform contractors), processing lab, and the NCI central repository. The NCI support services contractor (a separate contract) will primarily provide support for the study fieldwork activities including providing support for provision of procedures and protocols, staff training (as required) at study sites, follow-up and tracing of participants who have left the IHCS's health plan and assist with data and specimen access. The study IT platform contractor (a separate contract) will provide a tiered-access study IT platform with integrated systems for study operations, participant data collection, study research data, study research data and specimen request and approval.

Grants are made by the Board of Trustees of Ohio Cancer Research taking into account studies and recommendations of the Scientific Review Committee. Grants are available to investigators in either nonprofit or for-profit institutions, offices or clinics within the State of Ohio. However, grants to investigators working for profit-making organizations may not include funds for capital equipment. Grants are made with the stipulation of their use by a particular individual or group who are known as the principal investigator in support of a specific program of research under his/her/their direction. Full professors or their equivalent are not eligible. Only tenure track, junior faculty or equivalent scientific staffs are generally considered as appropriate. Postdoctoral fellows, Research, research assistants, and graduate students are ineligible to apply as P.I.'s, but they may be included as support staff. The P.I. must show evidence of independence. Applicants must be within six years of their first independent research or faculty appointment. Well established investigators should not submit projects related to their current area of research. Investigators previously funded by Ohio Cancer Research must provide justification that this application is significantly different from the previously funded project. Information regarding the results of the previously funded proposal and the P.I.'s success in obtaining further national funding must also be provided. Grants awarded by Ohio Cancer Research are made to support research activities broadly related to cancer and leukemia. Certain types of projects are not recommended for support. Among these are purely clinical work of a non-research nature and requests for the sole purpose of equipping a laboratory.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high-value informatics research resources to serve current and emerging needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on supporting activities necessary for improved user experience and availability of existing, widely-adopted informatics tools and resources.  This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justifications for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field.  In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and/or deep engagement between the resource and the targeted research community should be described.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high-value informatics research resources to serve current and emerging needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCIs Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on supporting activities necessary for improved user experience and availability of existing, widely-adopted informatics tools and resources.This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justifications for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field.In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and/or deep engagement between the resource and the targeted research community should be described.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery. Also listed under U01 and U24

This Funding Opportunity Announcement (FOA) solicits renewal applications for Biobanks that will support the following NCI clinical trial programs: The NCI National Clinical Trials Network (NCTN; https://research.usc.edu/nci-national-clinical-trials-network-nctn-program/), and NCI Community Oncology Research Program (NCORP). The NCTN Biospecimen Bank (also referred to as NCTN Biobanks) will be responsible for collecting, processing, storing, and distributing well-annotated human specimens from patients with cancer who are participating in NCI-funded NCTN Phase II-III and other clinical treatment trials (CTEP/Division of Cancer Treatment and Diagnosis; DCTD). The main goal is to support NCTN with the state-of the-art banking infrastructure and operations including maintenance of up-to-date specimen inventory. The NCTN Biobanks will distribute to qualified investigators the biospecimens linked to high-quality clinical data (including treatment and outcome information) that are critical for developing and validating biomarkers for cancer diagnosis, prognosis and prediction of responses to therapy. The NCTN Biobanks will work in collaboration with NCTN Groups and Group Statistical and Data Management Centers as well as affiliated institutions to ensure effective operation. Each Biobank needs to maintain association with one specific NCTN Group and needs to be endorsed in that role by the group leaders. NCTN Biobanks will also support biobanking and storage of biospecimens from NCORP cancer control and prevention trials (NCORP/Division of Cancer Prevention; DCP).

This request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Foundation) to solicit innovative research in leukemia. Grants of $50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia. The WES Foundation is supporting leukemia research because it recognizes that significant advances in the understanding, diagnosis, and treatment of leukemia are needed to achieve the goal of "when everyone survives".  Renewal of initial research support may be considered for one or more additional years based upon productivity.

This Funding Opportunity Announcement (FOA) is a part of the Pediatric Preclinical Testing Consortium (PPTC) initiative. The PPTC will consist of in vivo and in vitro testing Research Programs (both supported under companion RFA-CA-14-018) and the PPTC Coordinating Center (supported under this FOA). The PPTC is designed to address key challenges associated with the development of new therapies for children with cancer by developing reliable preclinical testing data for pediatric drug candidates that can be used to inform new agent prioritization decisions. Effective prioritization is critical because of the large universe of drugs being developed for adult cancers, a number so large that no more than a small number can be studied in pediatric clinical trials. Identifying through preclinical testing those investigational agents most likely to have clinical activity for selected childhood cancers accelerates the pace at which treatments that are more effective than the current ones can be identified and incorporated into standard practice for children with cancer. The PPTC Research Programs, responsible for conducting the in vivo and in vitro testing of selected agents, will be focused on specific tumor types that are particularly relevant to pediatric oncology. The PPTC Coordinating Center, which is subject of this FOA, will be responsible for integrating the activities of the individual PPTC Research Programs to create a functional consortium for pediatric preclinical testing. Specifically, the PPTP-Coordinating Center will provide administrative coordination and infrastructure, data management and statistical support, as well as Consortium scientific coordination.